Migdal Insurance & Financial Holdings Ltd. Sells 1,948 Shares of Bristol-Myers Squibb (NYSE:BMY)

Migdal Insurance & Financial Holdings Ltd. cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 58.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,360 shares of the biopharmaceutical company’s stock after selling 1,948 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Bristol-Myers Squibb were worth $70,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Herold Advisors Inc. increased its position in shares of Bristol-Myers Squibb by 3.2% during the third quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company’s stock valued at $1,954,000 after buying an additional 1,051 shares during the period. Kestra Private Wealth Services LLC grew its holdings in Bristol-Myers Squibb by 9.5% in the third quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company’s stock worth $8,115,000 after purchasing an additional 12,121 shares during the period. Metis Global Partners LLC grew its holdings in Bristol-Myers Squibb by 14.8% in the third quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company’s stock worth $5,907,000 after purchasing an additional 13,122 shares during the period. Jmac Enterprises LLC grew its holdings in Bristol-Myers Squibb by 11.4% in the third quarter. Jmac Enterprises LLC now owns 12,171 shares of the biopharmaceutical company’s stock worth $706,000 after purchasing an additional 1,245 shares during the period. Finally, Signaturefd LLC grew its holdings in Bristol-Myers Squibb by 0.5% in the third quarter. Signaturefd LLC now owns 105,986 shares of the biopharmaceutical company’s stock worth $6,151,000 after purchasing an additional 564 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY opened at $48.30 on Friday. The firm has a fifty day moving average price of $51.25 and a 200-day moving average price of $51.57. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The stock has a market cap of $97.89 billion, a PE ratio of 12.51, a price-to-earnings-growth ratio of 1.49 and a beta of 0.39. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.82 earnings per share. Equities analysts anticipate that Bristol-Myers Squibb will post 6.47 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.97%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BMY shares. Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $61.18.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.